首页> 外文学位 >The Molecular Basis of Antibody Mediated Neutralization of Hepatitis C Virus.
【24h】

The Molecular Basis of Antibody Mediated Neutralization of Hepatitis C Virus.

机译:抗体介导的丙型肝炎病毒中和的分子基础。

获取原文
获取原文并翻译 | 示例

摘要

Hepatitis C virus (HCV) is positive strand, blood-borne, hepatotropic RNA virus that causes chronic infection in ∼170 million people worldwide and is the leading cause of liver transplantation in the United States. HCV entry and attachment is mediated by the envelope protein E2 through interaction with several cellular receptors including CD81, scavenger receptor B1 (SRB-1), claudin-1, and occludin, although the exact mechanism by which these receptors facilitate infection remains unclear, largely due to the absence of a structural model of E2. The production of neutralizing antibodies against E2 is thought to be important for controlling HCV infection, likely by blocking virus interaction with these receptors. To better understand the structural and molecular basis of antibody neutralization of HCV, which could be used to inform novel therapeutic or vaccine approaches, we generated a panel of 78 monoclonal antibodies (MAbs) against the E2 protein from HCV genotypes 1 and 2 and assessed their neutralizing activity in vitro. Using this approach and by performing mechanistic studies, we identified three neutralizing MAbs, H77.16, H77.39, and J6.36, that inhibit infection at a post-attachment step. Using a yeast display library of E2 protein variants, we mapped the critical binding residues of these MAbs to distinct regions of the E2 protein: H77.16 binds within the HVR1 and to a conserved CD81 binding region ∼125 amino acid residues C-terminal to the HVR1; H77.39 binds to conserved residues upstream of the hypervariable region (HVR1); and J6.36 binds to amino acid residues within HVR1 as well a site ∼150 amino acids C-terminal to HVR1. Receptor-binding inhibition studies using E2 demonstrated that H77.16 potently inhibits binding to SR-B1, H77.39 potently inhibits binding to SR-B1 and CD81, and J6.36 potently inhibits binding to SR-B1 and modestly inhibits binding to CD81. Further mechanistic studies demonstrated that MAb-mediated neutralization could be enhanced by increases in pre-incubation temperature and time and that these results were likely due to altered epitope exposure on the viral surface. Together, these data provide new insight into the mechanisms by which antibodies neutralize infection of HCV.
机译:丙型肝炎病毒(HCV)是一种正链,血源性,肝细胞性RNA病毒,在全世界约1.7亿人中引起慢性感染,并且是美国肝移植的主要原因。 HCV的进入和附着是由包膜蛋白E2通过与几种细胞受体(包括CD81,清道夫受体B1(SRB-1),claudin-1和occludin)的相互作用介导的,尽管这些受体促进感染的确切机制仍不清楚,很大程度上由于缺少E2的结构模型。人们认为,针对E2的中和抗体的产生对于控制HCV感染很重要,可能是通过阻断病毒与这些受体的相互作用来实现的。为了更好地了解HCV抗体中和的结构和分子基础(可用于指导新型治疗或疫苗方法),我们生成了一组针对HCV基因型1和2的E2蛋白的78种单克隆抗体(MAb),并对其进行了评估体外中和活性。使用这种方法并通过进行机理研究,我们确定了三种中和的单克隆抗体H77.16,H77.39和J6.36,它们在附着后步骤抑制感染。使用E2蛋白变体的酵母展示文库,我们将这些MAb的关键结合残基定位到E2蛋白的不同区域:H77.16在HVR1内结合并在保守的CD81结合区〜C端约125个氨基酸残基HVR1; H77.39与高变区(HVR1)上游的保守残基结合; J6.36与HVR1内的氨基酸残基以及HVR1的C端约150个氨基酸结合。使用E2进行的受体结合抑制研究表明,H77.16有效抑制与SR-B1的结合,H77.39有效抑制与SR-B1和CD81的结合,J6.36有效抑制与SR-B1的结合,并适度抑制与CD81的结合。进一步的机理研究表明,预培养温度和时间的增加可增强MAb介导的中和作用,并且这些结果可能是由于病毒表面上抗原决定簇暴露量的改变。总之,这些数据为抗体中和HCV感染的机制提供了新的见解。

著录项

  • 作者

    Sabo, Michelle Catherine.;

  • 作者单位

    Washington University in St. Louis.;

  • 授予单位 Washington University in St. Louis.;
  • 学科 Biology Virology.;Health Sciences Immunology.
  • 学位 Ph.D.
  • 年度 2013
  • 页码 138 p.
  • 总页数 138
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号